These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 4480024)

  • 1. [Serum zinc levels in the normal and anovulatory cycle and under oral contraceptive therapy (author's transl)].
    Hähn N; Fuchs C
    Arch Gynakol; 1974; 217(3):309-14. PubMed ID: 4480024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum levels of copper, iron, magnesium, calcium and zinc in women with a normal menstrual cycle, under treatment with oral hormonal contraceptives and in pregnancy].
    Hähn N; Paschen K; Haller J
    Arch Gynakol; 1972; 213(2):176-86. PubMed ID: 4678746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the combined steroidal contraceptives (Gynanovlar 21 and Lyndiol 2.5) on the human adrenocortical and ovarian activities.
    Zaki K; Kamal I; Talaat MM; Rashad S; Nour H
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):41-65. PubMed ID: 12256027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Zinc levels in pregnant women, under oral contraceptive therapy and in normal (ovulating) women.
    Purwar MB; Deshpande AS; Jawade SB
    Asia Oceania J Obstet Gynaecol; 1983 Jun; 9(2):151-4. PubMed ID: 6615326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lynestrenol 1 mg.-mestranol 0.1 mg: a new low dose oral contraceptive: a clinical study.
    Kamal I; Hefnawi F; Younis N
    Egypt Popul Fam Plann Rev; 1970 Jun; 3(1):11-5. PubMed ID: 12254506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
    Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
    J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combined oral contraceptive steroids on pituitary-ovarian function during the menstrual cycle of lactating women.
    Ryu K; Yu HK; Kwak HM; Hong SS
    Contraception; 1983 Mar; 27(3):299-310. PubMed ID: 6406140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy.
    Lussier-Cacan S; Xhignesse M; Desmarais JL; Davignon J; Kafrissen ME; Chapdelaine A
    Metabolism; 1991 Aug; 40(8):849-54. PubMed ID: 1907348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some aspects of studies with oral contraceptives in Indian women.
    Shah PN
    J Obstet Gynaecol India; 1966 Aug; 16(4):409-14. PubMed ID: 12262163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
    Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
    Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrinological studies in two patients with post contraceptive cyclic dysfunction.
    Adamopoulos DA; Loraine JA; Ginsburg J; Loudon NB
    Scott Med J; 1972 Aug; 17(8):270-4. PubMed ID: 4642685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.